A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : GO / Graves' orbitopathy

[Related PubMed/MEDLINE]
Total Number of Papers: 437
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   GO  (>> Co-occurring Abbreviation)
Long Form:   Graves' orbitopathy
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2021 18 F-FDG-PET/MRI in patients with Graves' orbitopathy. MTV, TLG
2021 A novel CD4+ CTL subtype characterized by chemotaxis and inflammation is involved in the pathogenesis of Graves' orbitopathy. CTLs, GH, MLR, scRNA-seq, TCR-seq
2021 A randomized comparative study of inferomedial vs. balanced orbital decompression. Analysis of changes in orbital volume, eyelid parameters, and eyeball position. LWDV, OD
2021 Altered expression profile of BAFF receptors on peripheral blood B lymphocytes in Graves' disease. AITD, BR3, GD, HC, HT, TACI
2021 Antioxidant Therapy in Graves' Orbitopathy. GD, ivGCs, ROS
2021 Antiphospholipid antibodies in patients with Graves' orbitopathy: preliminary data. abeta2GPI, aCL, aPL, APS
2021 Association between Clinical Activity Score and Serum Interleukin-6, Interleukin-8 and Interleukin-10 during Systemic Glucocorticoid Treatment for Active Moderate-to-Severe Graves' Orbitopathy. CAS, GC, GD, HC, ILs
2021 Association of fibroblast growth factor 10 with the fibrotic and inflammatory pathogenesis of Graves' orbitopathy. FGF, FGFR2b, IL, OFs, rh, si, TGF, TNF
2021 Asymmetric Graves' Orbitopathy. ---
10  2021 Beneficial effect of low-dose radioiodine ablation for Graves' orbitopathy: results of a retrospective study. IVGC, TTA
11  2021 Clinical relevance of estimating circulating interleukin-17 and interleukin-23 during methylprednisolone therapy in Graves' orbitopathy: A preliminary study. CAS, GD, IL-17, MP, TSHRAb
12  2021 Clinical value of functional thyrotropin receptor antibodies in Serbian patients with Graves' orbitopathy. TBII, TSH-R-Ab
13  2021 Genetic Profiling of Orbital Fibroblasts from Patients with Graves' Orbitopathy. HA, HAS
14  2021 Glucocorticoids in Graves' orbitopathy: mechanisms of action and clinical application. GC
15  2021 Graves' Orbitopathy: Current Concepts for Medical Treatment. ---
16  2021 Graves' Orbitopathy: Report of 82 cases. GD, MRI
17  2021 IgG4 as a Biomarker in Graves' Orbitopathy. CAS, GD, IgG4-RD
18  2021 Immunological Features of Paranasal Sinus Mucosa in Patients with Graves' Orbitopathy. CT, Th
19  2021 Impact of Graves Disease on Ocular Surface and Corneal Epithelial Thickness in Patients With and Without Graves Orbitopathy. CET, GD
20  2021 In vivo confocal microscopy assessment of meibomian glands microstructure in patients with Graves' orbitopathy. API, AWI, CAS, IVCM, MAD, MAI, MF, MGs, MOA, MSR
21  2021 Lid Flare Measurement with Lateral Midpupil Distances. ANOVA, LLF
22  2021 Mechanisms That Underly T Cell Immunity in Graves' Orbitopathy. Th
23  2021 Modulating gut microbiota in a mouse model of Graves' orbitopathy and its impact on induced disease. GD, hFMT
24  2021 Modulating TSH Receptor Signaling for Therapeutic Benefit. GD, HLA-DR, IGF-1R, TSHR
25  2021 Neferine suppresses autophagy-induced inflammation, oxidative stress and adipocyte differentiation in Graves' orbitopathy. IL
26  2021 Novel Approaches for Immunosuppression in Graves' Hyperthyroidism and Associated Orbitopathy. GC, GH
27  2021 Ocular motility changes after inferomedial wall and balanced medial plus lateral wall orbital decompression in Graves' orbitopathy: a randomized prospective comparative study. CT, IM-OD, ML-OD
28  2021 Oral selenium improved the disease activity in patients with mild Graves' orbitopathy. GD
29  2021 Oxidative Stress in Graves Disease and Graves Orbitopathy. GH
30  2021 Percentage of Myeloid Dendritic Cells in Peripheral Venous Blood Is Negatively Related to Incidence of Graves' Orbitopathy. DCs, GD, mDCs, PBMCs
31  2021 PERK mediates oxidative stress and adipogenesis in Graves' orbitopathy pathogenesis. ATF4, C/EBP, CSE, ER, PERK, PPARgamma, ROS, siRNA
32  2021 Predicting the Course of Graves' Orbitopathy Using Serially Measured TSH-Receptor Autoantibodies by Automated Binding Immunoassays and the Functional Bioassay. ROC, TRAb
33  2021 Predicting the Relapse of Hyperthyroidism in Treated Graves' Disease with Orbitopathy by Serial Measurements of TSH-Receptor Autoantibodies. ATD, GD, TRAb
34  2021 Predictive Factors for Changes in Quality of Life after Steroid Treatment for Active Moderate-to-Severe Graves' Orbitopathy: A Prospective Trial. AP, EUGOGO, VF
35  2021 Primary and secondary superior rectus recessions to correct vertical deviations in Graves' orbitopathy patients. BSV
36  2021 Proposal for Standardization of Primary and Secondary Outcomes in Patients with Active, Moderate-to-Severe Graves' Orbitopathy. CRO, PRO, RCTs
37  2021 Prostaglandin F2α and EP2 agonists, and a ROCK inhibitor modulate the formation of 3D organoids of Grave's orbitopathy related human orbital fibroblasts. Col, CTGF, ECM, FN, GHOFs, IL-1beta, IL-6, LOX, ROCK
38  2021 Relative selenium insufficiency is a risk factor for developing severe Graves' orbitopathy: a case-control study. ROC, Se
39  2021 Risk factors for Graves' Orbitopathy in surgical patients-Results of a 10-year retrospective study with review of the literature. GD, TPOAb, TRAb
40  2021 Role of Proprotein Convertase Subtilisin/Kexin Type 9 in the Pathogenesis of Graves' Orbitopathy in Orbital Fibroblasts. CAS, COX-2, HIF-1alpha, HO-1, ICAM-1, IL-1beta, MnSOD, NF-kappaB, PCSK9, PPARgamma, TBII, Trx
41  2021 Selenium in the Treatment of Graves' Hyperthyroidism and Eye Disease. GH, ROS
42  2021 Serum thyroglobulin is associated with orbitopathy in Graves' disease. GD, TPOAb, TgAb, TRAb
43  2021 Signal transducer and activator of transcription 3 as a potential therapeutic target for Graves' orbitopathy. siRNA, STAT3
44  2021 Statins Decrease the Risk of Orbitopathy in Newly Diagnosed Patients with Graves Disease. GD, HR, IQR
45  2021 Steroid-Resistant Graves' Orbitopathy Treated with Tocilizumab in Real-World Clinical Practice: A 9-Year Single-Center Experience. CAS, TRAb
46  2021 The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. EUGOGO, GD, RAI
47  2021 The Clinical Features of Graves' Orbitopathy with Elevated Intraocular Pressure. EUGOGO, IOP
48  2021 Treatment of moderate to severe orbitopathy: Current modalities and perspectives. ETA, EUGOGO
49  2021 Wnt signalling inhibits adipogenesis in orbital fibroblasts from patients with Graves' orbitopathy. OF
50  2020 4-Methylumbelliferone suppresses hyaluronan and adipogenesis in primary cultured orbital fibroblasts from Graves' orbitopathy. 4-MU, ELISA, HAS, qPCR
51  2020 A Promising Mouse Model of Graves' Orbitopathy Induced by Adenovirus Expressing Thyrotropin Receptor A Subunit. GD, RNA-Seq
52  2020 Altered Expression of CXCL13 and Its Chemokine Receptor CXCR5 on B Lymphocytes during Active Graves' Orbitopathy. ---
53  2020 Anti-IL-6 Receptor Tocilizumab in Refractory Graves' Orbitopathy: National Multicenter Observational Study of 48 Patients. BVCA, CAS, DON, EUGOGO, GD, IOP, TCZ
54  2020 Anti-oxidative and anti-adipogenic effects of caffeine in an in vitro model of Graves' orbitopathy. PPARgamma, ROS
55  2020 Antithyroid drugs in Graves' hyperthyroidism: differences between "block and replace" and "titration" regimes in frequency of euthyroidism and Graves' orbitopathy during treatment. ATD, GH, TBII, TPOAb
56  2020 Change in newly diagnosed Graves' disease phenotype between the twentieth and the twenty-first centuries: meta-analysis and meta-regression. GD
57  2020 Changes in ocular biomechanics after treatment for active Graves' orbitopathy. bIOP, CAS, EUGOGO, ivGCs, WEM
58  2020 Characteristics of Hyaluronan Synthesis Inhibition by 4-Methylumbelliferone in Orbital Fibroblasts. 4-MU, DFs, HA, OFs
59  2020 Chemokine Expression during Adipogenesis and Inflammation in Orbital Fibroblasts from Patients with Graves' Orbitopathy. IL, mRNA, TNF
60  2020 Cholesterol Serum Levels and Use of Statins in Graves' Orbitopathy: A New Starting Point for the Therapy. GD, IVGC, OFs
61  2020 Clinical relevance of T lymphocyte subsets in pediatric Graves' disease. GD
62  2020 Comparative assessment of gut microbial composition and function in patients with Graves' disease and Graves' orbitopathy. GD
63  2020 Comparison of efficacy and safety of parenteral versus parenteral and oral glucocorticoid therapy in Graves' orbitopathy. GC
64  2020 Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves' orbitopathy. CAS, GD, TRAbs
65  2020 Corticosteroid Pulse Therapy for Graves' Ophthalmopathy Reduces the Relapse Rate of Graves' Hyperthyroidism. ATD, mPDS
66  2020 Current Knowledge on Graves' Orbitopathy. GCs, GD
67  2020 Descemetocele and bilateral, severe Pseudomonas keratitis in an intensive care unit patient with Graves' orbitopathy: A case report. EK, ICU
68  2020 Distinctive Features of Orbital Adipose Tissue (OAT) in Graves' Orbitopathy. BAT, BRITE, FA, Mfn2, OAT, OAT-GO, UCP1, WAT
69  2020 Downregulation of Caveolin-1 and Upregulation of Deiodinase 3, Associated with Hypoxia-Inducible Factor-1α Increase, Are Involved in the Oxidative Stress of Graves' Orbital Adipocytes. Cav-1, DIO3, eNOS, GLUT4, HIF, IHC, NO, NOX, WB
70  2020 Dysthyroid optic neuropathy: evaluation and management. CS, DON, EOM, OCT
71  2020 Efficacy of orbital radiotherapy in moderate-to-severe active graves' orbitopathy including long-lasting disease: a retrospective analysis. CAS, CON, EOM, RT
72  2020 Efficacy of rituximab in patients with Graves' orbitopathy: a retrospective multicenter nationwide study. RTX
73  2020 Efficacy Profile and Safety of Very Low-Dose Rituximab in Patients with Graves' Orbitopathy. CAS, ON, RTX
74  2020 Evaluation of IL-29 in Euthyroid Patients with Graves' Orbitopathy: A Preliminary Study. AUC, CAS, CI, CS, GD, IL-29
75  2020 Evaluation of Ocular Versions in Graves' Orbitopathy: Correlation between the Qualitative Clinical Method and the Quantitative Photographic Method. ---
76  2020 Evidence for Associations Between Th1/Th17 "Hybrid" Phenotype and Altered Lipometabolism in Very Severe Graves Orbitopathy. GC, GD, IFN-gamma, IL-17A, RORgammat
77  2020 Factors associated with severity of orbitopathy in patients with Graves' disease. CAS, GD, IOP, TRAb, ULN
78  2020 Glycogen Synthase Kinase-3β Mediates Proinflammatory Cytokine Secretion and Adipogenesis in Orbital Fibroblasts from Patients with Graves' Orbitopathy. COX-1, GSK-3beta, ICAM-1, MCP-1, NF, PPARgamma, RT-PCR
79  2020 Graves' disease. GD, IGF1R, TSHR
80  2020 Is concomitant treatment with steroids and radiotherapy more favorable than sequential treatment in moderate-to-severe graves orbitopathy? CAS, GCs, RT
81  2020 Is There Evidence for IGF1R-Stimulating Abs in Graves' Orbitopathy Pathogenesis? IGF-1Rs, IGF1RAbs, TSH
82  2020 Isolation and Characterization of Extraocular Muscle-Derived Muscle Progenitor Cells from Normal and Graves' Orbitopathy Patients. EOM-MPCs, EOMs, IFN, IL, MSCs, TNF
83  2020 Life-threatening complications of high doses of intravenous methylprednisolone for treatment of Graves' orbitopathy. EUGOGO
84  2020 Management of Graves Thyroidal and Extrathyroidal Disease: An Update. GD, MMI, RAI
85  2020 Measurement of proptosis using computed tomography based three-dimensional reconstruction software in patients with Graves' orbitopathy. CT
86  2020 Neutrophil-to-Lymphocyte, Monocyte-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Relation to Clinical Parameters and Smoking Status in Patients with Graves' Orbitopathy-Novel Insight into Old Tests. GD, NLR, PLR, WBC
87  2020 Novel Roles of Chloroquine and Hydroxychloroquine in Graves' Orbitopathy Therapy by Targeting Orbital Fibroblasts. CQ, HCQ, OFs, PCR, PM, RFP
88  2020 Preliminary evidence of the association between DNAm and orbital volumetry in GO. CT, TOA
89  2020 Protein tyrosine phosphatase 1B as a therapeutic target for Graves' orbitopathy in an in vitro model. bTSH, CSE, ELISA, ER, IGF-1, IL, JNK, PTP1B, ROS, SMA, TGF, TNF
90  2020 Putative protective role of autoantibodies against the insulin-like growth factor-1 receptor in Graves' Disease: results of a pilot study. GC, GD, IGF-1R, IGF-1RAbs, TRAbs
91  2020 Quantification of Global Ocular Motility Impairment in Graves' Orbitopathy by Measuring Eye Muscle Ductions. AR, b-TMS, GO-QoL, IVMP, TMS
92  2020 Results of surgical correction of upper eyelid retraction in Graves' Orbitopathy. ALDM
93  2020 Retinal, choroidal and optic disc analysis in patients with Graves' disease with or without orbitopathy. CAS, GCL, GD
94  2020 Role of binding immunoglobulin protein (BiP) in Graves' orbitopathy pathogenesis. BiP, ER, ROS, siRNA
95  2020 Search of reference biomarkers reflecting orbital tissue remodeling in the course of Graves' orbitopathy. GD
96  2020 Semi-automatic magnetic resonance imaging based orbital fat volumetry: reliability and correlation with computed tomography. CI, CT, ICC, MRI
97  2020 Teprotumumab: a disease modifying treatment for graves' orbitopathy. ---
98  2020 The feasibility of quantitative MRI of extra-ocular muscles in myasthenia gravis and Graves' orbitopathy. EOM, FF, HC, LOA, MG
99  2020 The Potential Link between Gut Microbiota and Serum TRAb in Chinese Patients with Severe and Active Graves' Orbitopathy. OTUs, TRAb
100  2020 The potential markers involved in newly diagnosed graves' disease and the development of active graves' orbitopathy. GD, ROC